Andere talen Biogen Inc.

Aandelen

BIIB

US09062X1037

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 11-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
172,50 ^USD	-2,84%		-5,21%	+12,80%

11:38	Analisten waarschuwen voor risico's bij herschikking Nasdaq 100-index voor Strategy	RE
10/12	BIOGEN INC. : Wells Fargo Securities is neutraal gestemd over het aandeel	ZM

Andere talen

Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	11:38
PREVIEW-Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	11:37
Wall Street : This is decision day	10/12
This Is Decision Day	10/12
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	10/12
Biogen : “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List	09/12
Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	05/12
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen	05/12
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen	05/12
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting	05/12
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting	05/12
Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option	04/12
Eisai Co., Ltd. and Biogen Inc. Present New Data	04/12
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	04/12
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025	04/12
Health Care Up on Alzheimer's Hopes - Health Care Roundup	03/12
Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference	02/12
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF	02/12
Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025	02/12
Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen	02/12
Tyra Biosciences, Inc. Appoints Heather Faulds as Chief Regulatory Officer, Effective December 8, 2025	01/12
Sector Update: Health Care Stocks Mixed Premarket Friday	28/11
Sector Update: Health Care	28/11
Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection	28/11
Eisai Announces New Drug Application for Subcutaneous Formulation of Leqembi Subcutaneous Formulation Ofleqembi Subcutaneous Form Formulation of Leqemab	28/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Biogen Inc.

Aandelen

BIIB

US09062X1037

Farmaceutische producten

Andere talen

Filters